Platelet-Rich Plasma (PRP) Treatment for Bedsores in Patients with Spinal Cord Injury

A Randomized Controlled Trial Evaluating the Efficacy of Autologous Platelet-Rich Plasma for Treating Grade 3 or 4 Sacral Pressure Ulcers in Spinal Cord Injury Patients - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/087472

Enrollment

Registered

2025-05-23

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S341- Other and unspecified injury of lumbar and sacral spinal cord

Interventions

Intervention1: Autologous Platelet-Rich Plasma (PRP) therapy: Name of Intervention: Autologous Platelet-Rich Plasma (PRP) Therapy Type: Biological Autologous Blood Product Route of Administration: L

Eligibility

Inclusion criteria

Inclusion criteria: SCI below C6 level Grade 3 or 4 sacral pressure ulcers Age 18-58 years Specific pressure ulcer size and duration range No active ulcer infection Ability to follow pressure relief protocols Written informed consent Non-smoker

Exclusion criteria

Exclusion criteria: Bleeding disorders, thrombocytopenia, or malignancy Immunosuppressant/antiretroviral medication use Active systemic infection Fever, severe allergies, recent injection site surgery Inability to understand or follow study instructions Uncontrolled seizures, severe osteoporosis Active psychological conditions limiting cooperation Diabetes mellitus, peripheral vascular disease

Design outcomes

Primary

Measure	Time frame
To evaluate the impact of Platelet-Rich Plasma (PRP) therapy on the reduction of surface area in grade 3 or 4 sacral pressure ulcers in spinal cord injury patients.Timepoint: Baseline (Week 0) Weekly for 4 weeks (i.e., Weeks 1, 2, 3, 4) Bi-weekly till Week 6 (i.e., Weeks 5 and 6) Monthly follow-up at Week 8 and Week 12 Final evaluation at 3 months	—

Secondary

Measure	Time frame
PUSH score, wound volume, Bates-Jensen score SF-36, WHODAS 2.0, SCIM Correlation analysis with clinical-demographic variablesTimepoint: Baseline (Week 0) Weekly for 4 weeks (i.e., Weeks 1, 2, 3, 4) Bi-weekly till Week 6 (i.e., Weeks 5 and 6) Monthly follow-up at Week 8 and Week 12 Final evaluation at 3 months	—

Countries

India

Contacts

Public ContactDr RAVI GAUR

All India Institute of Medical Sciences (AIIMS), Jodhpur

ravisms80@gmail.com8299711753

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026